The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX insider sale notice: A Form 144 filing lists an intended sale of 15,000 shares of Common Stock on 05/13/2026 through Fidelity Brokerage Services LLC on NASDAQ. The excerpt also lists multiple recent dispositions by Richard B. Bartram totaling large block sales from 03/16/2026 through 05/11/2026.
MBX Biosciences Chief Medical Officer Salomon Azoulay reported an exercise-and-sell transaction in company stock. On 2026-05-08, he exercised options to acquire a total of 70,003 shares of common stock at strike prices of $16.00 and $10.46 per share, then sold 70,003 shares in open-market transactions.
The sales occurred at weighted average prices of $38.30 and $38.38 per share, with individual trades executed between $35.00 and $41.26, under an approved Rule 10b5-1 trading plan adopted on January 27, 2026. Following these transactions, Azoulay directly holds 14,769 common shares.
He also retains stock options, including grants that had 30,008 and 194,540 options outstanding after the reported exercises, subject to vesting schedules that began vesting 25% on June 24, 2025 and September 12, 2025, with the remaining 75% vesting in 36 monthly installments.
MBX reported Form 144 sales and related option information by an affiliate. The filing lists multiple open-market dispositions by Richard B. Bartram: 10,000 shares on 03/16/2026, 1,061 shares on 03/25/2026, 10,423 shares on 04/22/2026, 5,000 shares on 05/01/2026, 10,000 shares on 05/07/2026, and 10,000 shares on 05/08/2026, each with the cash proceeds shown in the filing. The notice also lists option grants that may underlie future sales (examples include 5,000 shares, 5,000 shares, 7,500 shares, and 5,000 shares tied to grant dates). This filing is a disclosure of recent dispositions and option-related holdings; it reports transactions rather than corporate actions.
MBX Biosciences provided a comprehensive update on its obesity and peptide-therapy pipeline, highlighted by initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity. In the first multiple ascending dose cohort, preliminary blinded data showed mean weight loss of 7% at eight weeks in eight participants (including two on placebo), with only one mild gastrointestinal event and no serious adverse events. Pharmacokinetic data from single- and multiple-dose cohorts demonstrated gradual accumulation, a delayed time to peak concentration around 13–14 days, and a T1/2Cmax of about 26 days, all supporting the potential for true once-monthly dosing.
The company also nominated MBX 5765, an amycretin prodrug combining GLP-1, GIP, glucagon and DACRA activity, as a once-monthly obesity candidate slated for IND-enabling studies in Q2 2026, and plans to nominate a triple agonist in Q3 2026. Once-weekly imapextide achieved proof of concept in post-bariatric hypoglycemia with dose-dependent improvements in glucose nadir and insulin peak, though MBX will not pursue a Phase 2b trial as it reallocates resources toward canvuparatide and its obesity portfolio. Management reiterated multiple 2026 catalysts and noted unaudited cash, cash equivalents and marketable securities of $440 million as of March 31, 2026, expected to fund operations into 2029.
MBX reported Rule 144 notice of proposed sales of Common Stock. The filing lists two option-based lots designated for sale on 05/08/2026: 15,003 shares (option granted 09/12/2024) and 55,000 shares (option granted 08/02/2024), both noted as Cash Common. The filing also records a recent sale by Salomon Azoulay of 231 Common shares on 05/06/2026 for $6,824.78.
MBX Biosciences Chief Medical Officer Salomon Azoulay reported a small routine sale of company stock. On May 6, 2026, Azoulay sold 231 shares of common stock in an open-market transaction at a weighted average price of $29.54 per share.
According to the disclosure, these shares were sold to cover tax obligations triggered by the vesting of restricted stock units under a mandatory sell-to-cover agreement with the company. After this transaction, Azoulay directly holds 14,769 shares of MBX Biosciences common stock, indicating this was a minor, tax-related disposition rather than a large change in ownership.
MBX Biosciences President & CEO P. Kent Hawryluk reported a small share sale primarily to cover taxes. On May 6, he sold 607 shares of common stock at a weighted average price of $29.54 per share to satisfy tax obligations tied to vesting restricted stock units under a mandatory sell-to-cover arrangement.
After this transaction, he directly holds 727,667 common shares and also has 486,777 shares held indirectly through the P. Kent Hawryluk Revocable Trust dated January 25, 2011. The filing notes that he disclaims beneficial ownership of the trust shares except to the extent of any pecuniary interest.
MBX reporting proposed sales of common stock under Form 144, listing multiple option-originated share lots and recent open-market dispositions. The filing lists proposed sales of 10,000 shares through Fidelity Brokerage Services and shows prior sales totaling several reported transactions between 03/16/2026 and 05/07/2026.
The excerpt names three option grants with 2,500, 2,500, and 5,000 shares tied to grant dates and indicates cash settlement method for the listed option exercises.
MBX reports proposed and recent sales of common stock by a holder and brokerage entries. The filing lists proposed sales of 10,000 shares through Fidelity Brokerage Services LLC and two issuer‑granted option exercises to sell 5,000 shares each, all dated 05/07/2026. It also discloses four completed sales by Richard B. Bartram: 10,000 shares on 03/16/2026, 1,061 shares on 03/25/2026, 10,423 shares on 04/22/2026, and 5,000 shares on 05/01/2026, each with the reported sale proceeds shown in the filing.
MBX reports proposed and recent sales of common stock by a holder and brokerage entries. The filing lists proposed sales of 10,000 shares through Fidelity Brokerage Services LLC and two issuer‑granted option exercises to sell 5,000 shares each, all dated 05/07/2026. It also discloses four completed sales by Richard B. Bartram: 10,000 shares on 03/16/2026, 1,061 shares on 03/25/2026, 10,423 shares on 04/22/2026, and 5,000 shares on 05/01/2026, each with the reported sale proceeds shown in the filing.
MBX Biosciences reported a first quarter 2026 net loss of $23.5M, similar to a $23.9M loss a year earlier, as it continues investing in its endocrine and metabolic pipeline. Cash, cash equivalents and marketable securities were $440.0M as of March 31, 2026, which the company expects will fund operations into 2029.
R&D expenses fell to $18.5M while G&A expenses rose to $8.8M, reflecting both lower trial costs and ongoing infrastructure build-out. MBX highlighted progress for once-weekly canvuparatide in hypoparathyroidism, including planned Phase 3 initiation in Q3 2026, expansion of its obesity portfolio around MBX 4291 and new candidates, and Phase 2 advancement of imapextide for post-bariatric hypoglycemia.
MBX Biosciences reported a first quarter 2026 net loss of $23.5M, similar to a $23.9M loss a year earlier, as it continues investing in its endocrine and metabolic pipeline. Cash, cash equivalents and marketable securities were $440.0M as of March 31, 2026, which the company expects will fund operations into 2029.
R&D expenses fell to $18.5M while G&A expenses rose to $8.8M, reflecting both lower trial costs and ongoing infrastructure build-out. MBX highlighted progress for once-weekly canvuparatide in hypoparathyroidism, including planned Phase 3 initiation in Q3 2026, expansion of its obesity portfolio around MBX 4291 and new candidates, and Phase 2 advancement of imapextide for post-bariatric hypoglycemia.